Impact Biomedical Inc. Receives US Patent for 3F™ Technology Platform

Impact Biomedical Inc. (IBO) has been issued a US patent for its 3F™ technology platform, which relates to unique compositions and methods for controlling infectious diseases. The patent expands IBO's 3F™ patent estate, which includes insect repellent compositions and anti-microbial applications. The 3F™ technology has potential applications in treating infectious diseases and has been shown to be effective against various pathogens. The global infectious disease market is projected to grow to $34B by 2023, representing a CAGR of 5.77%.

Impact Biomedical Inc. (IBO) has been granted a significant milestone in its ongoing efforts to combat infectious diseases. The company has secured U.S. patent No. 12,357,584 B2 for its 3F™ technology platform, which focuses on controlling infectious diseases through plant-based functional fragrances. This patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.

The patent represents a substantial addition to IBO's intellectual property portfolio, which already includes related technologies for insect repellents and antimicrobial applications internationally. The 3F™ technology's potential applications range from surface disinfectants to potential therapeutic treatments against significant pathogens. This dual-use potential substantially expands the technology's commercial applications.

The global infectious disease market is projected to grow from $21.7 billion in 2024 to $34 billion in 2023, representing a CAGR of 5.77% [1]. This market growth underscores the strategic value of IBO's patented technology. While the company is actively pursuing partnerships to commercialize the 3F™ technology in the US and globally, no specific commercialization timeline or partnership details were disclosed.

The pathway from patent to marketable product remains lengthy, particularly if therapeutic applications require clinical trials and regulatory approvals. However, the broad claims covering both compositions and methods of use provide robust protection for IBO's intellectual property.

The patent's issuance is a testament to IBO's commitment to discovering, developing, and patenting unique technologies to meet unmet needs in human healthcare. The company continues to explore opportunities to leverage this technology to address the growing challenges posed by infectious diseases.

References:
[1] https://www.stocktitan.net/news/IBO/impact-biomedical-inc-ibo-announces-3ftm-us-patent-rgbouurqaqrt.html